Impact of abciximab versus eptifibatide on length of hospital stay for PCI patients

Catheterization and Cardiovascular Interventions

Volumn 53, Issue 3, 2001, Pages 296-303

  Lage, Maureen J ^a   Barber, Beth L ^b   McCollam, Patrick L ^b   Bala, Mohan ^c   Scherer, Joel ^b  

^a MIAMI UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c CENTOCOR INC   (United States)

Author keywords

Hospital stay; Length of stay; Multivariate analysis; Postprocedural length of stay; Retrospective study; Sample selection model

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR;

ADULT; AGED; ARTICLE; CORONARY ARTERY DILATATION; DEMOGRAPHY; FEMALE; HEALTH INSURANCE; HEALTH STATUS; HEART CATHETERIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY DISEASE; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LENGTH OF STAY; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; MULTIVARIATE ANALYSIS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES;

EID: 0034946825     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.1170     Document Type: Article

References (43)

1. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary sapheneous vein grafts
2. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction
3. An overview of the results of the EPIC trial
4. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention
5. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors
6. Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective
7. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein-IIb/IIIa blockade
8. Outcomes at one year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomized trial
9. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
10. Randomised placebo-controlled trial of eptifibatide on complications of percutaneous coronary intervention
11. Care of acute myocardial infarction by non-invasive and invasive cardiologists: Procedure use, cost and outcome
12. The relationship between hospital length of stay and rate of death in heart failures
13. Hospital discharge decisions, health outcomes, and the use of unobserved information on case-mix severity
14. The hospital course and short term prognosis of patients presenting to the emergency room with decompensated congestive heart failure
15. Early readmission of elderly patients with congestive heart failure
16. Generalized models with selectivity
17. Sample selection as a specification error
18. Health care costs and outcomes: How should we evaluate real world data?
19. Estimating endogenous treatment effects in retrospective data analysis
20. Methods for using large databases in health care research: Problems and promises - Proceedings of the Third Biennial Regenstrief Conference
21. SSRI antidepressant selection and concomitant prescribing of anxiolytics and sedative-hypnotics: Evidence from primary care in the United Kingdom
22. Shorter hospital stays for angioplasty patients who receive abciximab
23. Refinement of the medicare diagnosis-related groups to incorporate a measure of severity
24. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables
25. Timeliness and quality of care for elderly patients with acute myocardial infarction under health maintenance organization vs fee for service insurance
26. Gender, racial, and geographic differences in the performance of cardiac diagnostic and therapeutic procedures for hospitalized acute myocardial infarction in four states
27. Regional variation across the United States in the management of acute myocardial infarction
28. Cardiology and the quality of medical practice
29. Economic issues in glycoprotein IIb/IIIa receptor therapy
30. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade during coronary intervention in the EPILOG trial
31. Length of hospital stay after acute myocardial infarction in the myocardial triage and intervention (MITI) project registry
32. Comorbidity as a correlate of length of stay for hospitalized patients with acute chest pain
33. The association of hospital volumes of percutaneous transluminal coronary angioplasty with adverse outcomes, length of stay, and charges in California
34. The effect of complications on length of stay
35. Effect of institutional volume and academic status on outcomes of coronary interventions: The IMPACT-II experience
36. Abciximab therapy in percutaneous intervention: Economic issues in the United States
37. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty
38. Costs and effects of c7E3 in high risk PTCA patients: An indirect analysis for the Netherlands
39. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/llIa receptor blockage by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization
40. The economics of IIb/IIIa therapy
41. A statistical model for the analysis of ordinal level dependent variables